Evidence map›Paper›PMID 42068063›Full record

ArticleFEBS open bio2026

Optimizing photoactivation of PA-mCherry for optical pooled CRISPR screens.

Sravasti Mukherjee, Giulia Zanetti, Bram van den Broek, Kees Jalink

Abstract read
In one paragraph

Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sravasti MukherjeeDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-4507-8509
Giulia ZanettiDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0009-0004-1526-6060
Bram van den BroekDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-1037-907X
Kees JalinkDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-7019-3440

Funding

flIMAGIN3D - HORIZON-MSCA-DN-2021 101073507NWO National Roadmap for Large-Scale Research Infrastructure NWO 184.036.012
6 · The paper itself

Abstract

Optical pooled CRISPR screens have become an attractive tool for the rapid identification of genes involved in biological processes. In such screens, mixed populations of cells, each with a single gene knocked out, are screened by microscopy for phenotypes of interest. Identified hit cells can then be tagged by photoactivation of a co-expressed marker, such as PA-mCherry, and subsequently isolated by FACS to identify the responsible guide RNA by next-generation sequencing. Photoactivation is typically performed by selective irradiation of cells with UV light, using either a digital mirror device (DMD), an external fixed UV laser, or, conveniently, by using the 405 nm laser line present in most confocal scanning microscopes. In this study, the latter approach is optimized for PA-mCherry, a bright red phototag used by us and others in optical pooled screens. We find that although normal scanning with intense 405 nm light can rapidly activate PA-mCherry, it also leads to rapid photobleaching. Instead, much higher cellular brightness is achieved by limiting intensity and pixel dwell time during scanning, as well as by slightly defocusing the laser. These results should help optimize cell tagging for genotype-phenotype mapping in optical pooled screens, as well as for other applications.

Indexed as

confocal microscopyoptical pooled screensPA‐mCherryphotoactivationphotobleaching

Identifiers

PMID42068063
PMCPMC13399135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.